← All trials
NCT05367843
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 20, 2022
- Primary completion
- Sep 30, 2022
- Completion date
- Jul 31, 2023
- First posted
- May 10, 2022
- Last posted
- Sep 30, 2022
- Enrollment
- 144
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Speransa TherapeuticsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.